Metronidazole Shortage: What Providers and Prescribers Need to Know in 2026

Metronidazole remains a cornerstone antibiotic for anaerobic and protozoal infections. While oral formulations are generally available in 2026, IV metronidazole has experienced notable manufacturing-related shortages in the past, and providers should be prepared with clinical protocols for substitution. This guide summarizes the current availability landscape, evidence-based alternatives by indication, and communication strategies for affected patients.

Current Availability Status: 2026 Summary

Oral tablets (250 mg, 500 mg): Broadly available. No active FDA shortage listing. Generic widely stocked at most retail and mail-order pharmacies.

Extended-release oral (750 mg): Variable availability. Not stocked at all retail pharmacy locations. May require patient to check multiple pharmacies.

IV formulation: Historically at risk. Manufacturing concentration in a limited number of facilities makes this formulation susceptible to supply disruptions. Hospital pharmacies should monitor FDA and ASHP shortage databases actively.

Topical and vaginal formulations: Variable. Brand-name versions (Metrogel, Nuvessa) may be harder to locate. Generic equivalents more available.

Why IV Metronidazole Is Particularly Vulnerable to Shortages

The IV metronidazole shortage that emerged from Hospira manufacturing delays exemplifies a systemic vulnerability in the U.S. sterile injectable drug supply. Several structural factors contribute to this risk:

Limited manufacturer diversity: A small number of manufacturers produce the bulk of sterile injectable generics. Market exit by one major supplier creates a supply vacuum.

FDA manufacturing quality requirements: cGMP compliance issues can trigger facility shutdowns or production holds, instantly impacting available supply.

Low profit margins: Generic injectable drugs often have thin margins, making capital investment in manufacturing redundancy less economically attractive.

Evidence-Based Alternatives by Clinical Indication

When metronidazole is unavailable or contraindicated, the appropriate alternative depends on the clinical indication. The following guidance reflects current IDSA, CDC, and ASHP recommendations:

Bacterial Vaginosis

First-line alternative: Clindamycin 300 mg PO BID x 7 days, or clindamycin 2% vaginal cream once daily x 7 days. CDC recommends clindamycin as the preferred alternative for metronidazole-allergic patients.

Additional options: Tinidazole 2 g PO once daily x 2 days or 1 g PO once daily x 5 days; secnidazole 2 g PO single dose (Solosec). One-month cure rates for all of these are comparable to metronidazole (approximately 61%).

Trichomoniasis

Preferred alternative: Tinidazole 2 g PO single dose. Tinidazole exhibits lower resistance rates against T. vaginalis than metronidazole and is the preferred agent for metronidazole-resistant cases. Tinidazole's plasma half-life (~14 hours vs. metronidazole's ~8 hours) allows for more convenient single-dose therapy.

Note: For patients allergic to all nitroimidazoles, intravaginal boric acid and paromomycin have been used in refractory cases. Refer to infectious disease specialist for true nitroimidazole allergy.

Clostridioides difficile Infection

Current IDSA/SHEA guideline preference: Oral vancomycin 125 mg PO QID x 10 days or fidaxomicin 200 mg PO BID x 10 days. Metronidazole is no longer first-line for C. diff per current guidelines due to inferior efficacy compared to vancomycin and fidaxomicin.

Metronidazole's role in C. diff: May still be used for non-severe episodes when vancomycin or fidaxomicin are unavailable or unaffordable, per shared decision-making with the patient.

Anaerobic Infections and Surgical Prophylaxis

IV alternatives for surgical prophylaxis (colorectal, GYN): Clindamycin IV plus aminoglycoside or fluoroquinolone. Alternatively, cefoxitin or cefotetan provide anaerobic coverage in beta-lactam-tolerant patients.

Oral substitution for IV: Oral metronidazole is bioequivalent to IV metronidazole and should be substituted whenever the clinical situation permits (hemodynamically stable patient with functioning GI tract).

Patient Communication Strategies During Shortage

When a patient cannot fill a metronidazole prescription, clear communication is essential to prevent treatment gaps that could worsen their infection or lead to unnecessary ED visits:

Send an updated prescription immediately: If an alternative is appropriate, electronically transmit the updated prescription to the patient's preferred pharmacy as soon as possible. Delays increase the risk of untreated infection.

Recommend medfinder for pharmacy search: Direct patients to medfinder.com/providers. medfinder will call pharmacies near your patient to confirm which ones have their medication in stock — reducing callbacks and improving prescription fulfillment rates.

Educate on appropriate alternatives: Many patients will ask whether they can just "get something else." Use the opportunity to explain why the specific alternative you've chosen is appropriate — this improves adherence.

The Bottom Line for Providers

Oral metronidazole is not in shortage in 2026, but IV formulations remain historically vulnerable and topical forms can be variably available. Familiarize your team with the indication-specific alternatives summarized above, and consider directing patients to medfinder when they can't locate stock. Also see our companion guide:

How to Help Your Patients Find Metronidazole in Stock: A Provider's Guide